High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma
2015 · Scientific Reports · 63 citations
https://doi.org/10.1038/srep16954
Y
Yu Zhu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
105
Papers
2.6K
Citations
29
h-index
53
i10-index
Yu Zhu is an academic researcher from Guangzhou University of Chinese Medicine. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Renal cell carcinoma treatment. The author has an h-index of 29, co-authored 90 publications.
ORCID: 0000-0002-3332-5202Papers by this author
worksPan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer
2022 · ESMO Open · 38 citations
https://doi.org/10.1016/j.esmoop.2022.100518
B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients
2018 · BMC Cancer · 23 citations
https://doi.org/10.1186/s12885-018-4497-0
High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma
2014 · British Journal of Cancer · 22 citations
https://doi.org/10.1038/bjc.2014.179
<scp><i>TP53</i></scp> disruptive mutation predicts platinum‐based chemotherapy and <scp>PD‐1</scp>/<scp>PD‐L1</scp> blockade response in urothelial carcinoma
2024 · The Journal of Pathology · 9 citations
https://doi.org/10.1002/path.6266
Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer
2024 · Cancer Immunology Immunotherapy · 8 citations
https://doi.org/10.1007/s00262-024-03651-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat